{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:53:44Z","timestamp":1789937624963,"version":"4.0.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149388","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T18:53:03Z","timestamp":1455303183000},"page":"e0149388","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment"],"prefix":"10.1371","volume":"11","author":[{"given":"Jingwen","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"XM Ma","year":"2009","journal-title":"Nature reviews Molecular cell biology"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"DA Guertin","year":"2007","journal-title":"Cancer cell"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"M Laplante","year":"2012","journal-title":"Cell"},{"issue":"Suppl 2","key":"ref4","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"S Menon","year":"2008","journal-title":"Oncogene"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"DM Sabatini","year":"2006","journal-title":"Nature reviews Cancer"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"JJ Bissler","year":"2008","journal-title":"The New England journal of medicine"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncponc1112","article-title":"Rapamycin treatment for a child with germline PTEN mutation","volume":"5","author":"DJ Marsh","year":"2008","journal-title":"Nature clinical practice Oncology"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/gcc.20747","article-title":"Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis","volume":"49","author":"N Sato","year":"2010","journal-title":"Genes, chromosomes & cancer"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","article-title":"Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome","volume":"156","author":"S Menon","year":"2014","journal-title":"Cell"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"CC Dibble","year":"2012","journal-title":"Molecular cell"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.bcp.2010.06.029","article-title":"Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer","volume":"80","author":"K Mehta","year":"2010","journal-title":"Biochemical pharmacology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00726-010-0500-z","article-title":"Transglutaminase 2: a multi-functional protein in multiple subcellular compartments","volume":"39","author":"D Park","year":"2010","journal-title":"Amino acids"},{"issue":"13","key":"ref13","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.febslet.2010.04.072","article-title":"Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5","volume":"584","author":"M Frese-Schaper","year":"2010","journal-title":"FEBS letters"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"K Duvel","year":"2010","journal-title":"Molecular cell"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.chembiol.2005.02.007","article-title":"Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2","volume":"12","author":"K Choi","year":"2005","journal-title":"Chemistry & biology"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.4161\/auto.7.10.16681","article-title":"Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress","volume":"7","author":"S Ng","year":"2011","journal-title":"Autophagy"},{"issue":"16","key":"ref17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"N Hay","year":"2004","journal-title":"Genes & development"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"T Schmelzle","year":"2000","journal-title":"Cell"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"MA Bjornsti","year":"2004","journal-title":"Nature reviews Cancer"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00432-014-1803-3","article-title":"Current clinical regulation of PI3K\/PTEN\/Akt\/mTOR signalling in treatment of human cancer","volume":"141","author":"HJ Lim","year":"2015","journal-title":"Journal of cancer research and clinical oncology"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/156800908786733513","article-title":"mTOR pathway and mTOR inhibitors as agents for cancer therapy","volume":"8","author":"P Baldo","year":"2008","journal-title":"Current cancer drug targets"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"JS Carew","year":"2011","journal-title":"Targeted oncology"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"J Li","year":"2014","journal-title":"Cell metabolism"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1073\/pnas.1217602110","article-title":"PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies","volume":"110","author":"A Iwanami","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"A Britschgi","year":"2012","journal-title":"Cancer cell"},{"issue":"357","key":"ref26","doi-asserted-by":"crossref","first-page":"ra121","DOI":"10.1126\/scisignal.aaa1877","article-title":"Systematic identification of signaling pathways with potential to confer anticancer drug resistance","volume":"7","author":"CA Martz","year":"2014","journal-title":"Science signaling"},{"issue":"26","key":"ref27","doi-asserted-by":"crossref","first-page":"21796","DOI":"10.1074\/jbc.M111.304626","article-title":"The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)\/eukaryotic translation initiation factor 4E (eIF-4E)\/RAF pathway and activation is a mechanism of resistance","volume":"287","author":"B Hoang","year":"2012","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00726-011-1167-9","article-title":"Tissue transglutaminase: a new target to reverse cancer drug resistance","volume":"44","author":"A Budillon","year":"2013","journal-title":"Amino acids"},{"issue":"22","key":"ref29","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.1158\/0008-5472.CAN-06-1521","article-title":"Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation","volume":"66","author":"DS Kim","year":"2006","journal-title":"Cancer research"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1158\/0008-5472.CAN-06-1457","article-title":"Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway","volume":"66","author":"AP Mann","year":"2006","journal-title":"Cancer research"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/MCB.26.2.569-579.2006","article-title":"Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells","volume":"26","author":"H Yamaguchi","year":"2006","journal-title":"Molecular and cellular biology"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/156800907781662275","article-title":"Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity","volume":"7","author":"A Verma","year":"2007","journal-title":"Current cancer drug targets"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/onc.2009.342","article-title":"Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells","volume":"29","author":"GY Jang","year":"2010","journal-title":"Oncogene"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/carcin\/bgn158","article-title":"Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling","volume":"29","author":"L Cao","year":"2008","journal-title":"Carcinogenesis"},{"issue":"23","key":"ref35","doi-asserted-by":"crossref","first-page":"20127","DOI":"10.1074\/jbc.C200147200","article-title":"Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb","volume":"277","author":"JE Boehm","year":"2002","journal-title":"The Journal of biological chemistry"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1083\/jcb.148.4.825","article-title":"Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin","volume":"148","author":"SS Akimov","year":"2000","journal-title":"The Journal of cell biology"},{"issue":"21","key":"ref37","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/sj.onc.1209324","article-title":"Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells","volume":"25","author":"JF Herman","year":"2006","journal-title":"Oncogene"},{"issue":"17","key":"ref38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/sj.onc.1210035","article-title":"Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells","volume":"26","author":"LS Mangala","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"e13390","DOI":"10.1371\/journal.pone.0013390","article-title":"Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells","volume":"5","author":"A Kumar","year":"2010","journal-title":"PloS one"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3892\/etm.2015.2679","article-title":"Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel","volume":"10","author":"W He","year":"2015","journal-title":"Experimental and therapeutic medicine"},{"issue":"14","key":"ref41","doi-asserted-by":"crossref","first-page":"10115","DOI":"10.1074\/jbc.M113.464693","article-title":"A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival","volume":"289","author":"LK Boroughs","year":"2014","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bbrc.2011.11.094","article-title":"Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor","volume":"417","author":"Y Wang","year":"2012","journal-title":"Biochemical and biophysical research communications"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1021\/mp500405h","article-title":"Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention","volume":"12","author":"WP Katt","year":"2015","journal-title":"Molecular pharmaceutics"},{"issue":"9","key":"ref44","first-page":"2756","article-title":"Transglutaminase 2 in cancer","volume":"5","author":"L Huang","year":"2015","journal-title":"American journal of cancer research"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1535-7163.MCT-10-0912","article-title":"Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase","volume":"10","author":"M Khanna","year":"2011","journal-title":"Molecular cancer therapeutics"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2015.01.001","article-title":"NFkappaB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth","volume":"359","author":"X Zha","year":"2015","journal-title":"Cancer letters"},{"issue":"22","key":"ref47","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1158\/0008-5472.CAN-13-0560","article-title":"Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-beta-independent mechanism","volume":"73","author":"I Mikaelian","year":"2013","journal-title":"Cancer research"},{"issue":"22","key":"ref48","doi-asserted-by":"crossref","first-page":"18330","DOI":"10.1074\/jbc.M112.339317","article-title":"Ataxia-Telangiectasia, Mutated (ATM)\/Nuclear Factor kappa light chain enhancer of activated B cells (NFkappaB) signaling controls basal and DNA damage-induced transglutaminase 2 expression","volume":"287","author":"L Ai","year":"2012","journal-title":"The Journal of biological chemistry"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1073\/pnas.1119296109","article-title":"TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2\/serpinB2 and transglutaminase 2","volume":"109","author":"M Delhase","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ccr.2006.08.007","article-title":"Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival","volume":"10","author":"S Ghosh","year":"2006","journal-title":"Cancer cell"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0227851","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"record-id":"21990"},{"DOI":"10.1371\/journal.pone.0227851","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:56:24Z","timestamp":1718358984000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149388"}},"subtitle":[],"editor":[{"given":"Han-Ming","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149388","relation":{"expression_of_concern":[{"id-type":"doi","id":"10.1371\/journal.pone.0227851","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}